"Our culture of innovation and responsibility starts with our senior team and extends out to every member of the company. All of our staff and partners work
closely with Remedium Bio-Technology' senior team to maintain our focus of putting patients first to improve lives."
Chairman of the Board
and ChiefExecutjve Offcer
James Harrison-Flemming serves as our Chairman and Chief Executive Offcer and has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry, particularly in leading CNS transdermal patch and gel products through the entire product life cycle.
Prior to Remedium Bio Technology, James served as CEO of two publicly traded companies. Most recently, he was the CEO of a biotech company which was acquired by Teva Pharmaceuticals.
He led that company through FDA approval of its lead product, which was the first transdermal patch for migraine, to pre-launch before successfully over-seeing the sale of the company to Teva. He also served as President and CEO of a NASDAQ listed pharmaceutical company, where under his leadership, sales grew from $42 million to more than $260 million in just 6 years and market capitalization increased from $200 million to more than $900 million.
James received a B.S. in Molecular Biology from the University of Toronto - Mississauga, a Ph.D. in Biochemistry from York University, and conducted postdoctoral training in biophysics and biology at The Canadian Cancer Society Saskatchewan.
Daniel Priestley, Ph.D
Vice President, Product Development
Dr. Priestley is responsible for the day-to-day management of our research and development activities as well as supporting the commercialization of the company's products.
Dr. Priestley has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology.
Dr. Priestley has more than 30 years of executive, development and operational experience in the biopharmaceutical industry, particularly in CNS product development including epilepsy, pain, depression and schizophrenia. He has completed more than 10 regulatory submissions and approvals of new pharmaceutical products, including transdermal patch and gel products.
Prior to joining Remedium Bio Technology, Dr. Priestley held scientific leadership roles with Nivalis Therapeutics and Replidyne and also held research positions with OSI Pharma, Gilead Sciences and Amgen.
Dr. Priestley has a broad range of development experience, starting from early drug discovery and clinical trials through regulatory approval and commercial launch. He completed his Ph.D. at the University Of Alberta Faculty Of Science.
Simon Fullerton, Ph.D.
Director of Fonnulauon Sciences
Dr. Fullerton has more than IS years of experience developing formulations of pharmaceuticals, biologicals, and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal, and inhalation.
Previously, Dr. Fullerton successfully led the effort to develop, achieve regulatory approval, and complete manufacturing of Zecuity, the first transdermal patch for migraine.
Dr. Fullerton also led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase 1 clinical trial. He has a broad experience in early-stage R&D, formulation and process development, and technology transfer for GMP manufacturing.
Prior to joining Remedium Bio Technology he served in a variety of executive roles at GlaxoSmithKline for more than 20 years and has over-seen technical and project leadership roles at the McGill University, Quebec.
Dr. Fullerton graduated with a Ph.D. in Biochemistry and Genetics from York University, Toronto and conducted post-doctoral research at the Wilfrid Laurier University, Waterloo, Canada.
Daniel Essinger, PharmD
Vice President, Medical
Daniel Essinger, PharmD, has sewed as our Vice President, Medical since October 2010. Dr. Essinger is a senior pharmaceutical executive with more than 30 years of experience in clinical development, medical affairs and commercialization in CNS therapy areas.
During his career, he has led numerous successful clinical development programs, regulatory approvals and product launches. Prior to joining Remedium Bio Technology, he served as head of Medical Affairs for a large NASDAQ listed pharmaceutical company.
There he was instrumental in the clinical development of Imitrex and led the medical affairs teams in neurology and psychiatry. Additionally, he led several successful commercial product launches. He earned his Doctor of Pharmacy degree at the University of British Columbia and his MBA at the Trinity Western University.
He has published on the medical use of marijuana and differing experiences between men and women who use medicinal marijuana for Parkinson's disease tremor and has recently completed a clinical report on the findings.
Mr. Essinger also serves on the Board of Visitors at The School of Pharmacy at the University of Waterloo and as a board member of several nonprofit medical organizations.
Chief Financial Officer,
Harvey Millington serves as Remedium Bio Technology's Chief Financial Oficer, Corporate Development. Mr. Millington is a seasoned executive who has held management, financial and strategic planning roles in his 28-year tenure in the pharmaceutical industry.
Prior to Remedium Bio Technology, he was Senior Vice President, Chief Financial Offcer, at one of the world's most well-respected pharmaceutical giants and focused on their self-administered parenteral product range. He has also held the role of Chief Financial Offcer with Auxilium Pharmaceuticals, as well as additional general management, business development and strategic planning responsibilities with them.
Mr. Millington has over two decades of experience working with emerging growth companies and the investors that support them, including eight years Vice President with a Canadian biotech company that he helped take public and sell for nearly $200 million.
Mr. Millington holds a BS from the University of Manitoba and sits on several committees that explore the clinical benefits of medicinal marijuana for children.
Martin Miller, PhD
Director, Cannabinoid Research
Martin Miller, PhD, serves as Director of Cannabinoid Research. Dr. Miller is also an Adjunct Assistant Professor in the Department of Psychiatry at the McGill University, Montreal.
Prior to joining Remedium Bio Technology, he was a Research Health Science Specialist at the Canadian Centre on Substance Use and Addiction in Ottawa as well as sitting on the board at the National Center for Posttraumatic Stress Disorder, (PTSD), at The LifeLine Canada Foundation. He is also the former Executive Director at the Institute for Research on Cannabinoids, (IROC), in Colorado Springs, Colorado.
As an early research pioneer of marijuana comorbidity, Dr. Miller has spent over a decade investigating the interrelations between marijuana and a number of health conditions, including chronic pain, HIV, PTSD, and sleep disorders, for the purposes of treatment development and refinement. His research has spanned from laboratory-controlled to clinical trials and pre-implementation. Dr. Miller has published well over 100 peer-reviewed empirical publications, and he serves on the editorial boards of six scientific journals.
Dr. Miller earned a BA in psychology and PhD in clinical psychology from the University of Toronto and has also completed a pre-doctoral clinical
psychology internship at the Memorial University of Newfoundland and a joint postdoctoral fellowship at the Calgary Clinical Psychology institute.
Vice President, Commercial
Brian Gulliver serves as Remedium Bio Technology's Vice President, Commercial. Over his 25-year career in the pharmaceutical industry, Mr. Gulliver has held several leadership roles in marketing, sales, business development, analytics and alliance management.
Prior to Remedium Bio Technology, he was Vice President, Alliance & Strategic Portfolio Management of Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, where he managed the company's global portfolio.
Mr. Gulliver also held various roles of increasing responsibility at Auxilium, a specialty biopharmaceutical company. In his last role as Executive Director, Corporate Development & Licensing and Alliance Management, he participated in several transformational M&A, licensing and co-promotion deals through, and including, several international acquisitions.
Mr. Gulliver held senior managerial positions at Neurocrine Biosciences during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various U.S. and global commercial roles within specialty markets, including the treatments for neurological conditions and epilepsy.
Mr. Gulliver received a B.A. double major in Political Science/Policy and Management Studies from Dickinson College in Carlisle, Pennsylvania.
To deliver innovative medicines and advance patient care
With a shared vision philosophy, we align our capabilities to conduct ground-breaking clinical proven, innovative medicines to societies around the globe.